Disease of orbital part of eye adnexa

This study tests a new drug called AMG 732 for people with moderate-to-severe active thyroid eye disease, a condition that causes eye bulging and discomfort. The trial has two parts: Part A checks safety in healthy volunteers, and Part B tests how well the drug works in patients.…

This study tests a drug called AMG 732 in 30 adults with thyroid eye disease who either did not respond to treatment or saw their symptoms return after a previous study. The main goal is to see if the drug can reduce eye bulging by at least 2 millimeters without worsening the oth…

This early-stage trial is testing a new drug called cizutamig in 38 adults with active, moderate-to-severe thyroid eye disease. The main goal is to see if the drug is safe and tolerable, while also checking how the body processes it and whether it shows any signs of helping the c…

This study tests whether taking a statin (atorvastatin) and vitamin D can calm inflammation and reduce eye bulging in people with active thyroid eye disease. 120 adults will be randomly assigned to standard care alone, statin plus standard care, vitamin D plus standard care, or b…

This study tests an oral medication called tofacitinib in 8 people with moderate-to-severe thyroid eye disease who did not improve with or could not take steroids. The drug works by blocking inflammation pathways. Researchers will check if it reduces eye bulging and other symptom…

This Phase 3 trial tests MHB018A, an antibody injection, against placebo in 108 people with active moderate-to-severe thyroid eye disease. Participants receive six injections over 24 weeks. The main goal is to see if the drug reduces eye bulging by at least 2 mm without worsening…

This study tests a drug called MHB018A for people with moderate-to-severe thyroid eye disease, a condition that can cause bulging eyes and discomfort. About 258 adults who completed earlier studies will receive injections every 4 weeks. The main goal is to see if the drug reduces…

This Phase 3 trial tests an injection called MHB018A for people with chronic moderate-to-severe thyroid eye disease. The drug targets a protein linked to inflammation and eye bulging. About 150 adults will receive either the drug or a placebo every 4 weeks for 6 months. The main …

This study tests a drug called teprotumumab N01 in 50 adults with thyroid eye disease, an autoimmune condition that causes bulging eyes and discomfort. Participants receive the drug and are monitored with special PET and MRI scans to see if inflammation and eye changes improve. T…

This early-stage trial is testing a new drug called GenSci098 in 76 adults with active thyroid eye disease (TED). The main goal is to check the drug's safety and how the body processes it at different doses. Participants will receive either the drug or a placebo as a shot under t…

This study tests a new drug called ZL-1109 for people with moderate to severe thyroid eye disease, a condition that causes eye bulging and discomfort. About 99 Chinese adults will receive either the drug or a placebo to see if it safely reduces eye bulging by at least 2 millimete…

This Phase 3 trial tests IBI311 (teprotumumab) in 111 people with inactive thyroid eye disease. The main goal is to see if the drug can reduce eye bulging by at least 2 mm after 24 weeks. Participants receive either the drug or a placebo, and the study lasts up to 64 weeks.

This study compares sirolimus (an oral drug) to standard steroid infusions for treating active thyroid eye disease, a condition causing bulging eyes and discomfort. Researchers aim to see if sirolimus works better and causes fewer side effects. The trial involves 60 adults with m…

This study tests whether a new drug called IBI311 works better than standard steroid therapy for people with active moderate to severe thyroid eye disease. 64 participants will receive either IBI311 or steroids, and researchers will measure improvements in eye bulging, inflammati…

This study tests a drug called IBI311 in 50 people with inactive moderate-to-severe thyroid eye disease, a condition that can cause bulging eyes and double vision. IBI311 is an antibody that blocks a protein involved in the disease. The goal is to see if it improves eye symptoms …

This study tests a two-step treatment for people with moderate-to-severe thyroid eye disease (TAO) that is still active. First, patients receive high-dose steroids, then a newer drug called tetuzumab (IBI311) that blocks a growth factor receptor. The goal is to reduce bulging eye…

This study is observing how doctors manage complicated infections of the ears, nose, throat, and neck in both children and adults. Researchers will track standard treatments like surgery or medication to understand current practices. No new treatments are being tested; the goal i…

This pilot study is measuring prednisolone levels in 120 people with inflammatory diseases like thyroid eye disease, vasculitis, COPD, asthma, and others. Participants take high-dose prednisolone as part of their routine care, and researchers take timed blood samples to see how t…

This study looks at 100 people with Graves disease to see if inflammation and thyroid antibodies are linked to changes in the eye's nerve layer and macula. Researchers will compare eye scans (OCT) and blood tests between patients with and without eye involvement, plus healthy con…

This study uses a non-invasive eye tracker to measure how well people with Thyroid-Associated Ophthalmopathy (TAO) can move their eyes and pay attention to faces. Researchers will compare 100 participants, including patients and healthy volunteers, to see if the disease causes me…

This study investigates why some people with Graves' disease continue to feel mentally fatigued even after their thyroid levels return to normal. Researchers will compare blood and spinal fluid from 180 participants—60 with mental fatigue, 60 without, and 60 healthy controls—to f…